Show simple item record

dc.creatorCarbone, Michele
dc.creatorLednicky, John
dc.creatorXiao, Shu-Yuan
dc.creatorVenditti, Mario
dc.creatorBucci, Enrico
dc.date.accessioned2021-03-15T15:49:05Z
dc.date.available2021-03-15T15:49:05Z
dc.date.issued2021-01-07
dc.identifier.citationCarbone, M., Lednicky, J., Xiao, SY. et al. Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. Journal of Thoracic Oncology (2021). https://doi.org/10.1016/j.jtho.2020.12.014
dc.identifier.issn1556-0864
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/6205
dc.identifier.urihttp://hdl.handle.net/20.500.12613/6223
dc.description.abstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads mainly by means of aerosols (microdroplets) in enclosed environments, especially those in which temperature and humidity are regulated by means of air-conditioning. About 30% of individuals infected with SARS-CoV-2 develop coronavirus disease 2019 (COVID-19) disease. Among them, approximately 25% require hospitalization. In medicine, cases are identified as those who become ill. During this pandemic, cases have been identified as those with a positive SARS-CoV-2 polymerase chain reaction test, including approximately 70% who were asymptomatic—this has caused unnecessary anxiety. Individuals more than 65 years old, those affected by obesity, diabetes, asthma, or are immune-depressed owing to cancer and other conditions, are at a higher risk of hospitalization and of dying of COVID-19. Healthy individuals younger than 40 years very rarely die of COVID-19. Estimates of the COVID-19 mortality rate vary because the definition of COVID-19–related deaths varies. Belgium has the highest death rate at 154.9 per 100,000 persons, because it includes anyone who died with symptoms compatible with COVID-19, even those never tested for SARS-CoV-2. The United States includes all patients who died with a positive test, whether they died because of, or with, SARS-CoV-2. Countries that include only patients in which COVID-19 was the main cause of death, rather than a cofactor, have lower death rates. Numerous therapies are being developed, and rapid improvements are anticipated. Because of disinformation, only approximately 50% of the U.S. population plans to receive a COVID-19 vaccine. By sharing accurate information, physicians, health professionals, and scientists play a key role in addressing myths and anxiety, help public health officials enact measures to decrease infections, and provide the best care for those who become sick. In this article, we discuss these issues.
dc.format.extent26 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofCOVID-19 Research
dc.relation.haspartJournal of Thoracic Oncology
dc.relation.isreferencedbyElsevier
dc.rightsAttribution-NonCommercial-NoDerivs CC BY-NC-ND
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectCoronavirus
dc.subjectCOVID-19 transmission
dc.subjectPandemic
dc.titleCoronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
dc.typeText
dc.type.genreJournal article
dc.contributor.groupCenter for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine (Temple University)
dc.description.departmentBiology
dc.relation.doihttps://doi.org/10.1016/j.jtho.2020.12.014
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeTemple University. College of Science and Technology
dc.temple.creatorBucci, Enrico
refterms.dateFOA2021-03-15T15:49:05Z


Files in this item

Thumbnail
Name:
Bucci-JournalArticle-2021.pdf
Size:
2.173Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs CC BY-NC-ND
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs CC BY-NC-ND